A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Completed
AbbVie
Phase 2
2013-02-25
The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or
without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant
recipients with hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4) infection.
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
Completed
AbbVie
Phase 3
2013-12-01
This is a phase 3, double-blinded, multicenter study. The study will consist of 2 substudies:
Substudy 1 (SS1) will be double-blinded and enroll non-cirrhotic subjects and Substudy 2
(SS2) will be open label and enroll subjects with compensated cirrhosis.
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection
Completed
AbbVie
Phase 3
2014-01-01
This is a Phase 3, randomized, open-label, multicenter study, enrolling non-cirrhotic and
cirrhotic subjects. The purpose of this study is to evaluate the efficacy and safety of
ABT-450/r/ABT-267 co-administered with weight-based RBV for 12 or 16 weeks in adult chronic
HCV genotype 2-infected treatment-naïve and interferon (IFN) treatment-experienced subjects
with and without compensated cirrhosis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
